ArticleJournal of neuro-oncology2025
A novel lesion severity index to predict 90-day postoperative survival in brain metastasis patients.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBrain metastasis patients require granular surgical risk evaluation. The authors aimed to improve prognostication for brain metastasis patients by creating the Metastatic Brain Lesion Score (MBLS).
methodsThis is a retrospective cohort study of patients undergoing craniotomy for brain metastasis between Jan 1, 2014 and Sept 30, 2021 at a large tertiary referral center. Patients were excluded if they had craniotomy for non-metastatic lesions, radiation necrosis, or skull metastases only. The primary outcome was to define factors that predicted mortality at 90 days. Secondary measures were mFI-11 and RPA classifications. Multivariable logistic regression analyses were conducted to identify the clinically and statistically relevant predictors for the predicted mortality at 90 days with the creation cohort (n = 548). The metric developed was validated with the new data (validation cohort, n = 318), and was compared its prediction performance with secondary measures.
results866 consecutive patients (n = 548 creation cohort, n = 318 validation cohort) were reviewed and analyzed. Score factors included in the MBLS were: age > 65 (OR 1.97 (95%CI 1.19-3.02)), presence of supra- and infratentorial metastases (OR 1.696 (1.04-2.78)); hemorrhagic metastasis (OR 1.699 (1.09-2.64)); chronic opiate use (OR 2.34 (1.43-3.84)); poor functional status (OR 1.90 (1.22-2.97)); and presence of deep brain/brainstem lesions (OR 2.01 (1.07-3.78)). 61/164 (37.2%) creation cohort patients and 51/116 (43.9%) validation cohort patients with MBLS score ≥ 3 were deceased at 3 months. High-risk patients in the creation cohort were significantly more likely to be deceased 3 months postoperatively (OR 3.699 (95%CI 2.41-5.682), P < 0.001). In the validation cohort, MBLS was highly predictive (OR 5.311 (95%CI 3.06-9.22), P < 0.001) with a c-statistic of 0.696.
conclusionsThe MBLS provides "high-risk" surgical categorization for brain metastasis patients. By using preoperative characteristics obtainable from imaging and chart review, it can be utilized in preoperative discussions, giving a clearer view of potential postoperative course and outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.